Model systems of prostate cancer: Uses and limitations

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 361-371

  Navone, Nora M ^a   Logothetis, Christopher J ^a   Von Eschenbach, Andrew C ^a   Troncoso, Patricia ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell lines; LNCaP; MDA PCa 2a; MDA PCa 2b; PC 3; Xenografts

Indexed keywords

ANIMAL CELL; CANCER GROWTH; CANCER STAGING; DOG; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW; TRANSGENIC MOUSE; XENOGRAFT;

EID: 0032811310     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006165017279     Document Type: Review

References (73)

1. Landis SH, Tong T, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 48: 6-30, 1998
2. Dunning WF: Prostate cancer in the rat. J Natl Cancer Inst Monogr 12: 351-369, 1963
3. Lubaroff DM, Canfield L, Reynolds CW: The Dunning tumors. Prog Clin Biol Res 37: 243-263, 1980
4. Isaacs JT, Weissman RM, Coffey DS, Scott WW: Concepts in prostatic cancer biology: Dunning R. 3327 H, HI, and AT tumors. Prog Clin Biol Res 37: 311-323, 1980
5. Isaacs JT, Yu GW, Coffey DS: The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol 19(1): 20-23, 1981
6. Quarmby VE, Beckman WC Jr, Cooke DB, Lubahn DB, Joseph DR, Wilson EM, French FS: repression and localization of androgen receptor in the R. 3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50(3): 735-739, 1990
7. Isaacs JT, Isaacs WB, Feitz WF, Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9(3): 261-281, 1986
8. Isaacs JT: The aging AC1/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res 44(12 Pt 1): 5785-5796, 1984
9. Pugh TD, Chang C, Uemura H, Weindruch R: Prostatic localization of spontaneous early invasive carcinoma in Lobund Wistar rats. Cancer Res 54(22): 5766-5770, 1994
10. Lucia MS, Bostwick DG, Bosland M, Cockett ATK, Knapp DW, Leav I, Pollard M, Rinker Schaeffer C, Shirai T, Watkins BA: Workgroup 1: Rodent models of prostate cancer. Prostate 36(1): 49-55, 1998
11. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von Eschenbach AC, Chung LW: Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 87(1): 75-79, 1990
12. Chang SM, Chung LW: Interaction between prostalic fibroblast and epithelial cells in culture: role of androgen. Endocrinology 125(5): 2719-2727, 1989
13. Rowley DR, Characterization of a Fetal urogenital sinus mesenchymal cell line U4F: secretion of a negative growth regulatory activity. In vitro Cell Dev Biol 28A(1): 29-38, 1992
14. Gerdes MJ, Dang TD, Lu B, Larsen M, McBride L, Rowley DR, Androgen-regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS-1). Endocrinology 137(3): 864-872, 1996
15. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ: Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 36(1): 64-67, 1998
16. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG: Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 30(2): 92-97, 1997
17. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH: Experimental oncogene induced prostate cancer. Cancer Surv 11: 55-71, 1991
18. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH: Transgenic models for the study of prostate cancer. Cancer 71(3): 1165-1171, 1993
19. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G: Loss of p53 function leads to metastasis in ras + myc initiated mouse prostate cancer. Oncogene 10(5): 869-879, 1995
20. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC: Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1: 1111-1118, 1995
21. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993
22. Navone NM, LaBate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ: p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urology 161(1): 304-308, 1999
23. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen insensitive mouse prostate cancer cells. Nat Med 4(9): 1062-1064, 1998
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM: Prostate cancer in a transgenic mouse. Proc Nati Acad Sci USA 92: 3439-3443, 1995
25. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth, ML, Matusik RJ: Development, progression, and androgen dependence of prostate tumors in probasin large T antigen transgenic mice: a model for cancer. Lab Invest 78(6): i-xv, 1998
26. Cleutjens KB, van der Korput HA, Ehren van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J, A 6-kb promoter fragment mimics in transgenic mice the prostate specific and androgen regulated expression of the endogenous prostate specific antigen gene in humans. Mol Endocrinol 11(9): 1256-1265, 1997
27. Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91(23): 11236-11240, 1994
28. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM: Androgen independent prostate cancer progression in the TRAMP model. Cancer Res 57(21): 4687-4691, 1997
29. Stapleton AMF, Timme TL, Gousse AH, Li QF. Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino TL, Thompson TC: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3: 1389-1392, 1997.
30. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S: The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 48: 971-979, 1996
31. Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI: Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 36(1): 59-63, 1998
32. Ellis WJ, Vassella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH: Characterization of a novel androgen sensitive, prostate specific antigen producing prostate carcinoma xenograft: LuCaP 23. Clin Cancer Res 2: 1039-1048, 1996
33. Gittes RF: Carcinoma of the prostate. N Engl J Med 324: 236-245, 1991
34. Catalona WJ: Management of cancer of the prostate. N Engl J Med 331: 996-1004, 1994
35. Scher HI, Steineck G, Kelly WK: Hormone refractory (D3) prostate cancer: Refining the concept. Urology 46: 142-148, 1995.
36. Peehl DM: Culture of human prostatic epithelial cells. In: Culture of Epithelial Cells, Freshney RA (ed) Wiley-Liss, New York, pp 159-180, 1992
37. Chaproniere DM, McKeehan WL: Serial culture of single adult human prostatic epithelial cells in serum-free medium containing low calcium and a new growth factor from bovine brain. Cancer Res 46: 819-824, 1986
38. Konig JJ, van Dongen JW, Schroder FH: Preferential loss of abnormal prostate carcinoma cells by collagenase treatment. Cytometry 14: 805-810, 1993
39. Konig JJ, Teubel W, van Dongen JW, Hagemeijer A, Romijn JC, Schroder FH: Tissue culture loss of aneuploid cells from carcinoma of the prostate. Genes Chrom Cancer 8: 22-27, 1993
40. Jones F, Zhu XL, Rohr LR, Stephenson RA, Brothman AR: Aneusomy of chromosomes 7 and 17 detected by FISH in prostate cancer and the effect of selection in vitro. Genes Chrom Cancer 11: 163-170, 1994.
41. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983
42. Passaniti A, Isaacs JT, Haney JA, Adler SW, Cujdik TJ, Long PV, Kleinman HK: Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer 51: 318-324, 1992
43. Gleave M, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761, 1991
44. Veldscholte J, Ris Staplers C, Kuiper GGJM, Jenster G, Berrevoets C, Classen E, van Fooij HCJ, Trapman J, Brinkman AO, Muler E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173: 534-540, 1990
45. Wilding G, Chen M, Gelmann E: Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115, 1989
46. Kokontis J, Kiyoshi, Hiipakka RA, Kiao S: Expression and function of normal and LNCaP androgen receptors in androgen insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1: 271-270, 1991
47. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata OK, Keer HN, Balk SP: Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. N Engl J Med 332: 1393-1398, 1995
48. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152: 1-9, 1998
49. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2(2): 277-285, 1996
50. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Barisch G, Klocker H, Cato ACB: Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding. Int J Cancer 63(4): 544-550, 1995
51. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55(14): 3068-3072, 1995
52. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP: Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147(6): 1608 -1614, 1995
53. Cunha GR: The role of androgens in the epitheliomesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 175(1): 87-96, 1973
54. Cunha GR, Chung LW: Stromal-epithelial interactions - 1. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 14(12): 1317-1324, 1981
55. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57(3): 406-412, 1994
56. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW: Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCap and lineage-derived metastatic sublines. Int J Cancer 77(6): 887-894, 1998
57. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach, AC, Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54(10): 2577-2581, 1994
58. Pettaway CA, Pathak S, Greene G, Tamirez E, Wilson MR, Killion JJ, Fidler IJ: Selection of highly metastatic variants of different human prostate carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2: 1627-1636, 1996
59. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler JJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 84(12): 951-957, 1992
60. Chen ME, Lin SH, Chung LW, Sikes RA: Isolation and characterization of PAGE 1 and GAGE 7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma associated antigens. J Biol Chem 273(28): 17618-17625, 1998
61. McConkey DJ, Greene G, Pettaway CA: Apoptosis resistance increases with metastatic potential in cells of the human LNCap prostate carcinoma line. Cancer Res 56(24): 5594-5599, 1996
62. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu S-M, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3: 2493-2500, 1997
63. Kaighn ME, N Shankar, Ohnuki Y, Lechner F, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC. 3). Investigative Urol 17: 16-23, 1979
64. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU145). Intl J Cancer 21: 274-281, 1978
65. Iizumi T, Yazaki T, Kanon S, Kondo I, Koiso K: Establishment of a new prostatic carcinoma cell line (TSU. PrI). J Urol 137(6): 1304-1306, 1987
66. Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chang LWK: Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93: 15152-15157, 1996
67. Hoehn W, Schroeder FH, Reimann JF, Joebsis AC, Hermanek P: Human prostatic adenocarcinoma: some characteristics of serially transplantable line in nude mice (PC 82). Prostate 1(1): 95-100, 1980
68. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, et al.: Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 85(5): 394-398, 1993
69. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11(4): 450-459, 1997
70. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56(13): 3042-3046, 1996
71. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ: Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 149(3): 1055-1062, 1996
72. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belidegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med 3(4): 402-408, 1997
73. Olumi AF, Dazin P, Tlsty TD: A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCap cells by retarding cell death. Cancer Res 58(20): 4525-4530, 1998